Indian drugmakers readying for next “Patent cliff”
The strategic drug reviews, as well as mergers and acquisitions – such as Actavis buying out Forest for around $25 billion – that are playing out on the global stage have a bearing on India, with Big Pharma seeking to refocus operations and battle an imminent patent cliff, writes The Pharma Letter’s Indian correspondent.
Though patent expiries are great news for consumers, with cheaper generics available on the market, they are also a big financial boost for generic drug makers. With some 46 US drug patents set to expire by 2015, Indian companies stand to benefit by around $40 billion, according to rough estimates.
Patent cliff
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze